Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
November 02, 2023 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
August 30, 2023 16:05 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
June 26, 2023 08:30 ET
|
Acer Therapeutics Inc.
Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer...
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
May 15, 2023 17:10 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
May 01, 2023 08:30 ET
|
Acer Therapeutics Inc.
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at...
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023 16:01 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
March 22, 2023 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 22, 2023 08:00 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
March 17, 2023 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...